Pharmaceuticals Company Announces Promising Results In Breast Cancer Cell Growth Inhibition

Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), known for its innovative approach in enhancing cancer treatments through radiation therapy, has announced promising developments with one of its pre-clinical assets, SP-1-303. The selective histone deacetylase (HDAC) inhibitor has demonstrated substantial growth inhibition of estrogen receptor-positive breast cancer cells (ER+ BC) by activating the ataxia-telangiectasia mutated (ATM) protein and modulating estrogen receptor (ER) expression. These findings were published in the peer-reviewed journal, PLOS ONE. $Shuttle Pharmaceuticals(SHPH.US)$